- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07458594
Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer (CCRP-AD)
March 4, 2026 updated by: Yue Dou, Beijing Sport University
Effects of Combined Caffeine and Rhodiola Rosea Supplementation on Aerial Duel Performance Under Fatigue in Soccer Players
This study will examine whether caffeine (CAF) and Rhodiola rosea (RHO) supplementation, taken alone or in combination, can improve explosive performance and soccer-specific aerial duel performance in trained male soccer players.
In a randomized, double-blind, placebo-controlled, parallel design, participants will be assigned to placebo, RHO, CAF, or RHO+CAF for 4 weeks.
Performance outcomes will be assessed before and after the intervention using countermovement jump measures (including early take-off impulse) and standardized heading tests (heading reach height, ball exit velocity, and heading duel success rate), with additional measures of neck isometric strength and perceived exertion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Sport University
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100084
- China Football Institute, Beijing Sport University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male soccer players from the Beijing Sport University team.
Systematic soccer-specific training background and stable competitive level.
Suitable for high-intensity physical testing based on the Physical Activity Readiness Questionnaire (PAR-Q).
Exclusion Criteria:
- History of neuromuscular or musculoskeletal system diseases.
Intake of caffeine (coffee/tea), other supplements, ergogenic aids, or alcohol within the last 3 months.
Current use of antidepressants or central nervous system stimulants.
Smokers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Control Group (CTR)
Participants receive empty capsules (containing starch or rice flour) identical to the active supplements for 30 days.
|
Appearance-matched capsules containing inert ingredients (starch or rice flour).
|
|
Experimental: Rhodiola Rosea Group (RHO)
Daily supplementation of 2.4g Rhodiola rosea extract (approx.
12mg salidroside) for 30 days, taken in two doses before breakfast and lunch.
|
Standardized Rhodiola rosea extract capsules.
Daily total dosage of 2.4 g (containing approx.
12 mg salidroside), taken twice daily (before breakfast and lunch) for 30 days.
|
|
Experimental: Caffeine Group (CAF)
A single dose of 3 mg/kg body mass of anhydrous caffeine administered 30 minutes before exercise testing.
|
Anhydrous caffeine capsules administered at a dose of 3 mg/kg body weight.
Taken as a single dose 30 minutes prior to the physical performance tests.
|
|
Experimental: Combined Rhodiola and Caffeine Group (RHO + CAF)
Combined daily supplementation of 2.4g Rhodiola rosea for 30 days and a single 3 mg/kg dose of caffeine before testing.
|
Standardized Rhodiola rosea extract capsules.
Daily total dosage of 2.4 g (containing approx.
12 mg salidroside), taken twice daily (before breakfast and lunch) for 30 days.
Anhydrous caffeine capsules administered at a dose of 3 mg/kg body weight.
Taken as a single dose 30 minutes prior to the physical performance tests.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early takeoff impulse (Impulse₀-₂₀₀)
Time Frame: Baseline (Day 0) and Post-intervention (Day 30), measured under both non-fatigued and fatigued conditions.
|
Calculated as the integration of vertical force over the first 200 ms of the countermovement jump (CMJ) takeoff phase, relative to body mass (N·s·kg-¹).
This measures the capacity for rapid force production.
|
Baseline (Day 0) and Post-intervention (Day 30), measured under both non-fatigued and fatigued conditions.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heading contact height
Time Frame: Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
Participants perform a header and touch a football suspended on a vertical jump tester with their forehead.
The highest touch height from three trials is recorded to reflect aerial reach capacity.
|
Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
|
Heading Ball Velocity
Time Frame: Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
The maximum velocity of the ball after heading is measured using a speed device.
A ball machine is used to ensure consistent delivery direction and speed.
This measures momentum transfer efficiency and technical execution.
|
Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
|
Aerial Duel Success Rate
Time Frame: Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
Calculated as the percentage of successful duels out of a fixed number of trials in a standardized head-to-head setting.
Success is defined as effectively contacting the ball first and directing it toward a target area.
|
Baseline (Pre-test) and 4 weeks (Post-test), including measurements under both non-fatigued and fatigued conditions at each time point.
|
|
Neck Isometric Strength
Time Frame: Baseline (Pre-test) and 4 weeks (Post-test).
|
Maximum isometric force measured in neck flexion and extension using a handheld dynamometer.
Values are normalized to body mass ($N \cdot kg^{-1}$) to assess the stability of the head-trunk system.
|
Baseline (Pre-test) and 4 weeks (Post-test).
|
|
Rate of Perceived Exertion (RPE)
Time Frame: Immediately after the fatigue-induction protocol and post-fatigue testing at Baseline and 4 weeks.
|
Subjective effort level reported by participants on a scale of 1 to 10 (1 = nearly no effort, 10 = extreme effort) immediately following the fatigue protocol and post-fatigue tests.
|
Immediately after the fatigue-induction protocol and post-fatigue testing at Baseline and 4 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2025
Primary Completion (Actual)
December 27, 2025
Study Completion (Actual)
January 3, 2026
Study Registration Dates
First Submitted
March 4, 2026
First Submitted That Met QC Criteria
March 4, 2026
First Posted (Actual)
March 9, 2026
Study Record Updates
Last Update Posted (Actual)
March 9, 2026
Last Update Submitted That Met QC Criteria
March 4, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025602H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared due to participant confidentiality and institutional data protectionpolicies.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aerial Duel Performance in Soccer Players
-
Universidad de AntioquiaClub La NororientalCompletedDecision Making in Soccer Players and Executive FunctionsColombia
-
Beijing Sport UniversityCompletedPsychological Self-talk Interventions in Soccer PerformanceChina
-
Merve KeskinNot yet recruitingPhysical Performance and Postural Stability in Healthy Male Basketball PlayersTurkey (Türkiye)
-
Fenerbahce UniversityCompletedHealthy | Volleyball Players | Neuromuscular Performance | Healthy Adult Male | Injury Prevention in SportsTurkey (Türkiye)
-
Karamanoğlu Mehmetbey UniversityCompletedPerceptual Motor Performance and Neural Conduction Asymmetries in Elite Basketball PlayersTurkey (Türkiye)
-
Gulf Medical UniversityNot yet recruitingDynamic Balance, Hop Performance and Maximum Voluntary Ventilation (MVV) in Professional Football PlayersUnited Arab Emirates
-
Imam Abdulrahman Bin Faisal UniversityNot yet recruitingThe Study Investigates the Efficacy of Core Stability Training on Core Endurance and Kinetic Chain Function and Dynamic Balance in Healthy Adult Soccer Players
-
Beijing Sport UniversityCompletedPhysical Performance and Fatigue in Competitive Football PlayersChina
-
Emirates Health Services (EHS)Lincoln University College MalaysiaActive, not recruitingLong-Term Eccentric, Concentric & Combined Hamstring Training Improves Strength, May Cut Injury Risk, and Enhances Performance in Elite Male Football PlayersUnited Arab Emirates
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States